Indrayani Biotech Limited has announced a board meeting scheduled for April 9, 2026, to deliberate on a significant corporate restructuring proposal. The company filed a regulatory notice on April 6, 2026, informing the BSE about the upcoming board deliberations.

Board Meeting Details

The board meeting has been convened under Regulation 29 of the SEBI (LODR) Regulations, 2015, with a specific focus on evaluating a demerger proposal. The primary objective of this corporate action is to unlock shareholder value through strategic restructuring.

Demerger Proposal Overview

The proposed demerger involves separating one of the company's units into a separate entity. This corporate restructuring strategy is designed to create distinct business entities that can operate independently, potentially leading to enhanced operational efficiency and improved market valuation.

The company's board will deliberate and evaluate the various aspects of this demerger proposal during the scheduled meeting. Such corporate actions typically require comprehensive analysis of financial implications, regulatory compliance, and strategic benefits.

Trading Window Status

Indrayani Biotech Limited has confirmed that the trading window for dealing in the company's securities remains closed. This closure is in connection with the upcoming declaration of financial results and will continue until 48 hours after the results are made public.

The regulatory filing was signed by Ramya Ravi, Company Secretary and Compliance Officer, ensuring proper corporate governance and regulatory compliance in the announcement process.

Indrayani Biotech Limited has fulfilled its quarterly regulatory obligations by submitting the mandatory compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The submission demonstrates the company's adherence to securities market regulations governing dematerialization processes.

Regulatory Compliance Submission

The company submitted its Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 4, 2026. The certificate was addressed to both major depositories in India - National Securities Depository Limited and Central Depository Services (India) Limited. Company Secretary and Compliance Officer Ramya Ravi signed the submission letter on behalf of Indrayani Biotech Limited.

RTA Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, served as the Registrar and Transfer Agent for this compliance process. The RTA issued its confirmation certificate on April 3, 2026, one day prior to the company's submission to the depositories. Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited, signed the confirmation certificate.

Compliance Confirmations

The RTA certificate confirmed several critical compliance aspects for the quarter ended March 31, 2026:

• Securities received from depository participants for dematerialization were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were confirmed or rejected within prescribed timelines
• Received security certificates were mutilated and cancelled after due verification by the depository participant
• Names of the depositories were substituted in the register of members as registered owners within prescribed timelines

Stakeholder Notifications

The company ensured comprehensive stakeholder communication by copying BSE Limited on the submission. The notification was sent to BSE's Department of Corporate Services at their Dalal Street, Mumbai office, maintaining transparency with the listing authority regarding the compliance certification process.

This quarterly submission represents standard regulatory practice for listed companies, ensuring proper oversight of dematerialization activities and maintaining investor confidence in the securities handling process.